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Abstract: Five percent of papillary thyroid carcinomas (PTC) show an adverse clinical outcome
(ACO). The tall cell variant of papillary thyroid carcinomas (TCV) is a good predictor of an ACO,
however, the identification of tall-cells is subjective. Micro RNAs are short non-coding ribonucleic
acids (miRNA). Their expression in PTC could be a powerful, more objective predictor of prognosis.
Methods: Forty-four PTC underwent miRNA profiling, twenty-four of them were TCV. The miRNA
dataset was validated by analysis of expression of known target proteins (vascular endothelial growth
factor (VEGF) and phosphatase and tensin homolog (PTEN)) in 125 patients including 48 TCV and 57
with an ACO. Results: One hundred and forty-nine miRNAs were significantly associated with an
ACO, seventy-one of them with TC-morphology. Twenty-two miRNAs were identified as targets
for VEGF and thirty-two as targets for PTEN. In univariate and multivariable analysis, reduced
expression of PTEN and an increased expression of VEGF were associated with shorter relapse
free survival. A classifier, including TC-morphology, pT-stage, VEGF, and PTEN, predicted relapse
with an 80% accuracy. Conclusions: Some miRNAs predict outcome in PTC and are involved in
TC-morphology in PTC. These miRNAs may serve as more objective indicators of an ACO than tall
cell morphology. PTEN and VEGF protein expression are prognostically relevant and are at least
partially regulated by miRNAs.
Keywords: thyroid carcinoma; miRNA; PTEN; VEGF; prognosis; tall cell; TERT
1. Introduction
Thyroid carcinoma accounts for about 1% of all human malignant neoplasms [1]. Eighty-six percent
of these carcinomas are papillary thyroid carcinomas (PTC). These belong to the group of differentiated
thyroid cancers, which is known for its favorable prognosis [2] in contrast to poorly differentiated
or anaplastic thyroid carcinomas [3–5]. The standard therapy for PTC is thyroidectomy followed
by a radioiodine therapy (RAI), which generally cures the patient [6]. Nevertheless, 5% of PTC
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encountered by clinicians and pathologists do not follow this favorable course but rather behave
more aggressively [7]. Currently, there are several features known to correlate with such an adverse
outcome like pT-stage (gross extrathyroidal extension and tumor size) and patient age [2]. Furthermore,
morphological subtypes such as tall-cell variant have been identified as adverse prognosticators [7,8].
Although these features are recognized for patient management, the prediction of the clinical behavior
in an individual case remains difficult.
We have recently shown that even a small percentage of tall-cell (TC) morphology is of strong
prognostic importance [7]. Molecular markers to reliably identify TC are not known and the biology
behind this morphological phenomenon remains mostly elusive. A deeper understanding of the disease
would be important, since the identification of TC versus non-TC in a given tumor can be subjective
and is hampered by lack of experience and inter-observer variability.
Telomerase reverse transcriptase (TERT) promoter mutations are known to be a strong predictor
of an adverse outcome. However, the mutation is only found in about 7–8% of PTC of which all are TC
variants in our previous study [7]. Additional objective tools to reliably predict an adverse clinical
outcome (ACO), independent of TC morphology would be helpful.
Micro RNAs are short non-coding ribonucleic acids (miRNA). They are a class of non-coding
18–24 nucleotide long RNAs that play an important epigenetic regulatory role in nearly all cellular
processes including cancer development. They can either function as oncogenes, so called oncomiRs or
as tumor suppressing miRNAs by negatively regulating the gene expression of their target genes [9].
Their expression is tissue specific and so, specific tumor signatures have been developed for various
human malignancies including thyroid cancer and its subtypes [10–13].
Phosphatase and tensin homolog (PTEN) is known to play an important role as a tumor
suppressor gene in human cancers and thyroid carcinomas exhibit a decreased expression of
PTEN [14]. Amongst other functions, PTEN inactivates the Phosphoinositide-3-kinase/Protein kinase B
pathway, leading to tumor progression via the Phosphoinosito 3-kinase (PI3K)/Protein Kinase B(AKT)
pathway [15].
Vascular endothelial growth factor (VEGF) is a known stimulator of endothelial cell proliferation
and migration [16]. While some studies have suggested an aggressive clinical course in PTC with
VEGF overexpression, this could not be confirmed by others [17]. New VEGF-A and multi-tyrosine
kinase inhibitors like Lenvatinib are now on their way to the clinics and thus are a promising tool in
RAI refractory tumors [18].
In this study, we performed a comprehensive miRNA profiling to identify transcriptomic changes
on miRNA level in PTC and to evaluate if some of them could add prognostic value in individualized
patient management, independent from TC morphology. Further, we analyzed whether those miRNAs
may be involved in the development of TC morphology. We then used protein data of PTEN and VEGF,
two genes which are frequent targets of the found miRNAs to cross validate our miRNA expression
data. Lastly, we explored the prognostic role of these two genes in PTC.
2. Results
2.1. MiRNA Analysis
In total, 149 miRNAs were statistically significantly associated with a decreased relapse free
survival (Table 1).
Table 1. MiRNAs associated with decreased RFS (relapse free survival) and with TC (tall cell)
morphology (bold).
MiRNA p-Value (Mann U Test),Decreased RFS
p-Value (Mann U Test), Sign
with TC-Morphology
Expression Level of miRNA
Mean ± st. Error Mean
hsa-let-7a 0.001 1.68 ± 0.25
hsa-let-7c 0.001 1.01 ± 0.13
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Table 1. Cont.
MiRNA p-Value (Mann U Test),Decreased RFS
p-Value (Mann U Test), Sign
with TC-Morphology
Expression Level of miRNA
Mean ± st. Error Mean
hsa-let-7f 0.013 1.34 ± 0.24
hsa-let-7g 0.049 0.004 1.48 ± 0.31
hsa-miR-1 0.011 0.003 2.35 ± 0.63
hsa-miR-100-3p 0.001 0.004 3.77 ± 0.67
hsa-miR-106a-5p 0.017 0.002 1.58 ± 0.28
hsa-miR-106b-3p 0.001 2.49 ± 0.46
hsa-miR-107 0.005 1.23 ± 0.26
hsa-miR-1183 0.001 0.048 3.81 ± 0.76
hsa-miR-1243 0.001 2.41 ± 0.40
hsa-miR-1253 0.007 7.76 ± 1.95
hsa-miR-1254 0.002 2.81 ± 0.95
hsa-miR-1255b 0.005 1.32 ± 0.20
hsa-miR-1260 0.001 0.021 1.23 ± 0.19
hsa-miR-1262 0.001 0.05 20.07 ± 5.23
hsa-miR-126-5p 0.001 0.014 1.58 ± 0.34
hsa-miR-1271 0.002 3.30 ± 0.87
hsa-miR-1274b 0.047 1.10 ± 0.15
hsa-miR-1276 0.001 1.87 ± 0.40
hsa-miR-128 0.001 1.40 ± 0.29
hsa-miR-1285 0.002 1.27 ± 0.20
hsa-miR-1290 0.001 0.003 6.80 ± 1.88
hsa-miR-135b 0.001 0.002 4.04 ± 0.78
hsa-miR-136 0.001 0.0001 22.36 ± 6.26
hsa-miR-138 0.007 0.005 0.39 ± 0.07
hsa-miR-146b-5p 0.041 0.003 128.62 ± 23.62
hsa-miR-148a 0.028 0.029 0.53 ± 0.12
hsa-miR-149 0.003 1.71 ± 0.37
hsa-miR-15b 0.001 1.68 ± 0.33
hsa-miR-16 0.001 0.002 2.85 ± 0.60
hsa-miR-17 0.032 0.002 1.58 ± 0.28
hsa-miR-181a-2-3p 0.013 5.97 ± 1.05
hsa-miR-181c 0.001 0.0005 8.77 ± 3.18
hsa-miR-182 0.002 0.006 4.73 ± 1.56
hsa-miR-1825 0.021 2.61 ± 0.45
hsa-miR-183-3p 0.006 5.13 ± 1.26
hsa-miR-186 0.001 0.001 1.21 ± 0.23
hsa-miR-190 0.001 0.019 4.29 ± 2.88
hsa-miR-190b 0.001 4.08 ± 0.81
hsa-miR-191 0.041 0.007 1.44 ± 0.19
hsa-miR-195 0.001 0.001 1.08 ± 0.27
hsa-miR-196b 0.002 0.0004 4.56 ± 1.27
hsa-miR-197 0.004 0.001 2.05 ± 0.51
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Table 1. Cont.
MiRNA p-Value (Mann U Test),Decreased RFS
p-Value (Mann U Test), Sign
with TC-Morphology
Expression Level of miRNA
Mean ± st. Error Mean
hsa-miR-199a-5p 0.004 0.84 ± 0.15
hsa-miR-19b-1-5p 0.041 2.24 ± 0.45
hsa-miR-200b 0.001 0.001 2.50 ± 0.47
hsa-miR-202 0.001 16.08 ± 4.09
hsa-miR-206 0.001 0.005 12.16 ± 2.33
hsa-miR-20a 0.046 0.003 1.58 ± 0.45
hsa-miR-20a-3p 0.034 1.27 ± 0.34
hsa-miR-21 0.002 0.001 7.50 ± 1.79
hsa-miR-213 0.025 1.25 ± 0.19
hsa-miR-22 0.004 1.37 ± 0.31
hsa-miR-221 0.041 14.50 ± 2.27
hsa-miR-222 0.005 0.004 22.37 ± 4.75
hsa-miR-223 0.046 0.0004 1.02 ± 0.18
hsa-miR-22-5p 0.001 1.29 ± 0.23
hsa-miR-23b 0.006 1.54 ± 0.25
hsa-miR-24-2-5p 0.009 1.65 ± 0.23
hsa-miR-26a 0.004 0.001 1.0 ± 0.17
hsa-miR-26b 0.001 0.0001 1.78 ± 0.48
hsa-miR-26b-3p 0.028 2.05 ± 0.37
hsa-miR-28-3p 0.001 2.12 ± 0.46
hsa-miR-28-5p 0.001 0.81 ± 0.11
hsa-miR-29a 0.03 0.006 2.33 ± 0.43
hsa-miR-29c 0.017 0.018 2.83 ± 1.26
hsa-miR-301b 0.004 1.78 ± 0.49
hsa-miR-302d 0.022 1.58 ± 0.33
hsa-miR-30a-3p 0.003 0.98 ± 0.16
hsa-miR-30b 0.001 1.02 ± 0.14
hsa-miR-30c 0.032 0.92 ± 0.16
hsa-miR-30d 0.039 0.009 1.25 ± 0.2
hsa-miR-30e-3p 0.002 0.03 ± 0.17
hsa-miR-32 0.001 0.003 16.04 ± 8.09
hsa-miR-320 0.019 0.87 ± 0.09
hsa-miR-337-5p 0.021 0.002 2.39 ± 0.69
hsa-miR-339-3p 0.039 1.81 ± 0.31
hsa-miR-340 0.001 0.001 2.24 ± 0.50
hsa-miR-340-3p 0.001 1.92 ± 0.41
hsa-miR-34b 0.001 3.67 ± 0.75
hsa-miR-361-5p 0.022 0.008 1.36 ± 0.25
hsa-miR-362-5p 0.012 0.009 1.19 ± 0.16
hsa-miR-372 0.007 0.043 11.12 ± 3.49
hsa-miR-373 0.048 0.89 ± 0.23
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Table 1. Cont.
MiRNA p-Value (Mann U Test),Decreased RFS
p-Value (Mann U Test), Sign
with TC-Morphology
Expression Level of miRNA
Mean ± st. Error Mean
hsa-miR-374a 0.001 0.004 1.74 ± 0.47
hsa-miR-374b 0.01 1.03 ± 0.15
hsa-miR-376a 0.001 0.0003 3.30 ± 0.01
hsa-miR-376a-5p 0.004 2.48 ± 0.55
hsa-miR-376c 0.014 0.003 0.89 ± 0.21
hsa-miR-380-5p 0.029 0.62 ± 0.19
hsa-miR-411 0.028 0.003 0.89 ± 2.01
hsa-miR-423-5p 0.019 2.08 ± 0.66
hsa-miR-425-3p 0.001 4.17 ± 1.16
hsa-miR-429 0.001 0.002 4.39 ± 1.24
hsa-miR-454 0.001 0.003 1.85 ± 0.46
hsa-miR-483-5p 0.001 0.004 2.60 ± 0.46
hsa-miR-487a 0.003 0.05 10.96 ± 4.90
hsa-miR-488 0.006 1.27 ± 0.26
hsa-miR-489 0.001 0.017 2.99 ± 0.40
hsa-miR-493 0.022 0.022 1.58 ± 0.58
hsa-miR-494 0.001 0.003 3.31 ± 0.93
hsa-miR-497 0.009 0.46 ± 0.09
hsa-miR-500 0.004 0.77 ± 0.10
hsa-miR-505-5p 0.022 1.96 ± 0.44
hsa-miR-516-3p 0.001 0.023 4.98 ± 1.01
hsa-miR-518b 0.001 14.93 ± 7.34
hsa-miR-518f 0.013 113.54 ± 73.78
hsa-miR-520c-3p 0.001 0.035 4.94 ± 0.82
hsa-miR-523 0.001 22.64 ± 5.71
hsa-miR-532-3p 0.004 0.83 ± 0.13
hsa-miR-532-5p 0.001 4.55 ± 1.81
hsa-miR-539 0.002 0.01 4.35 ± 1.80
hsa-miR-545 0.001 0.004 3.15 ± 1.34
hsa-miR-545-5p 0.007 15.62 ± 8.79
hsa-miR-548a-3p 0.001 17.74 ± 5.17
hsa-miR-548c-3p 0.001 21.88 ± 5.93
hsa-miR-571 0.038 2.94 ± 0.64
hsa-miR-576-3p 0.001 0.002 2.47 ± 0.57
hsa-miR-577 0.001 0.027 1.34 ± 0.30
hsa-miR-586 0.015 8.92 ± 2.37
hsa-miR-590-3p 0.001 0.02 12.78 ± 6.23
hsa-miR-590-5p 0.001 0.004 4.46 ± 1.58
hsa-miR-591 0.004 1.21 ± 0.28
hsa-miR-601 0.001 14.79 ± 2.70
hsa-miR-606 0.004 9.23 ± 2.69
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Table 1. Cont.
MiRNA p-Value (Mann U Test),Decreased RFS
p-Value (Mann U Test), Sign
with TC-Morphology
Expression Level of miRNA
Mean ± st. Error Mean
hsa-miR-625 0.002 0.0002 3.65 ± 0.89
hsa-miR-625-3p 0.001 0.024 6.99 ± 1.97
hsa-miR-627 0.001 0.0001 6.13 ± 1.54
hsa-miR-628-5p 0.002 30.48 ± 14.89
hsa-miR-630 0.04 2.89 ± 0.85
hsa-miR-636 0.001 0.001 1.10 ± 0.25
hsa-miR-645 0.008 0.011 1.13 ± 0.19
hsa-miR-650 0.049 3.14 ± 1.12
hsa-miR-655 0.025 0.004 4.95 ± 2.20
hsa-miR-661 0.001 0.015 1.99 ± 0.34
hsa-miR-664 0.004 1.99 ± 0.36
hsa-miR-708 0.002 1.17 ± 0.23
hsa-miR-7-1 0.014 1.78 ± 0.32
hsa-miR-744-3p 0.001 1.55 ± 0.15
hsa-miR-758 0.001 4.81 ± 2.65
hsa-miR-767-3p 0.011 0.029 10.70 ± 4.58
hsa-miR-885-5p 0.021 0.003 8.35 ± 5.17
hsa-miR-892b 0.036 185.04 ± 156.31
hsa-miR-92a 0.001 0.024 1.69 ± 0.38
hsa-miR-92a-1-5p 0.008 0.77 ± 0.16
hsa-miR-93-3p 0.001 14.87 ± 7.51
hsa-miR-95 0.025 0.015 1.78 ± 0.84
hsa-miR-99b-3p 0.003 7.99 ± 1.78
MiRTarBase plus literature research was used to identify experimentally verified miRNA targets
of VEGF and PTEN [19]. An amount of 4076 miRNAs are currently listed in miRTarBase as verified
target-mRNA interactions of different genes and 125 miRNAs are listed as targets for PTEN and 122
for VEGF.
The bioinformatic target prediction tool mirDIP was used to identify miRNAs targeting PTEN and
VEGF [20]. When a miRNA was predicted in at least two different miRNA databases by mirDIP and it
was deregulated in the correct direction (upregulated), the Kaplan–Meier test for a decreased relapse
free survival in our dataset was run. This bioinformatic pipeline identified 22 miRNAs in our dataset
targeting VEGF and predicting a decreased relapse free survival (RFS; Table 2). Fifty four percent
of these VEGF-targeting miRNAs are also listed on the miRTarBase website. The same approach for
PTEN identified 32 miRNAs (Table 3) in total and 28% of them are listed in miRTarBase and in our
dataset. Applying the chi-square test to these numbers reveals that the miRNAs that were identified
by us are significantly overrepresented in miRTarBase (p <0.01 for VEGF and PTEN).
Seventy-one out of 149 miRNAs associated with a decreased RFS were significantly correlated with TC.
Among them are many well-known cancer-associated miRNAs like miR-1, miR-21 or miR-146b-5p (Table 1).
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Table 2. MiRNA predicted as target for vascular endothelial growth factor (VEGF) and with decreased RFS and PubMed Identifier (PMID) of miRNA–VEGF interaction
validated in other papers.
miRNA Predicted as
Target for VEGF and with
Decreased RFS
p Value
(Kaplan Meier,
Log Rank)
Dichotomized
at VEGF as Target of Identified miRNA Validated in Other Experiment, PMID
hsa-mir-1 0.052 1 27777493 28493075 27541266
hsa-mir-106a-5p 0.028 1.4 18320040 23807165 18320040 17242205
hsa-mir-1285-3p 0.011 1
hsa-mir-17-5p 0.048 1 18320040
hsa-mir-186-5p 0.000 1 27322147
hsa-mir-195-5p 0.033 1 18320040 22473208 23592263 24398324 23446348 22012620 21572407 20371350 23468064 26823724
hsa-mir-200b-3p 0.000 2 21544626 28122882 25884496
hsa-mir-202-3p 0.000 2
hsa-mir-206 0.000 1 27541266
hsa-mir-29c-3p 0.039 2 20371350 23592263 21572407 27000664
hsa-mir-302d-3p 0.019 1 18320040
hsa-mir-373-3p 0.003 0.5 18320040
hsa-mir-374a-5p 0.003 0.5 23446348
hsa-mir-429 0.001 2 26647818
hsa-miR-494-3p 0.001 1
hsa-mir-516a-3p 0.001 1
hsa-mir-520c-3p 0.001 1
hsa-mir-548a-3p 0.017 2
hsa-mir-548c-3p 0.019 1
hsa-mir-571 0.004 1
hsa-mir-590-3p 0.001 1
hsa-mir-645 0.013 1
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Table 3. MiRNA predicted as target for Phosphatase and tensin homolog (PTEN) and with decreased RFS and PMID of miRNA-PTEN interaction validated in
other papers.
miRNA Predicted as
Target for PTEN and
with Decreased RFS
p-Value
(Kaplan Meier,
Log Rank)
Dichotomized
at PTEN as Target of Identified miRNA Validated in Other Experiment, PMID
hsa-mir-106a-5p 0.028 1.4 28919047 24108762 26306906 26097565
hsa-mir-1183 0.002 1
hsa-mir-1255b-5p 0.009 1
hsa-mir-1285-3p 0.011 1
hsa-mir-1290 0.002 1
hsa-mir-136-5p 0.000037 1
hsa-mir-146b-5p 0.010 2
hsa-mir-17-5p 0.048 1 20227518 20008935 21283765 20388916 23418359 24220575 24901013 24912422 24462867 22473208 23391506 23433743
hsa-mir-181c-5p 0.000055 2 25695913
hsa-mir-186-5p 0.000 1
hsa-mir-190b 0.009 1 26692329
hsa-mir-200b-3p 0.000 2
hsa-mir-222-3p 0.001 10 20618998 19962668 23028614 23974492 23994196 27644883
hsa-mir-29c-3p 0.039 2 23143395
hsa-mir-302d-3p 0.019 1
hsa-mir-32-5p 0.001 2 23617834 22473208 24123284 23524257 28319142
hsa-mir-337-5p 0.024 2
hsa-miR-372-3p 0.035 3
hsa-mir-373-3p 0.003 0.5
hsa-mir-376a-3p 0.015 3
hsa-mir-429 0.001 2 24866238
hsa-miR-494-3p 0.001 1 20006626 22544933 25662849
hsa-mir-520c-3p 0.001 1
hsa-mir-539-5p 0.008 1.50
hsa-mir-545-3p 0.000266 2
hsa-mir-548a-3p 0.017 2
hsa-mir-548c-3p 0.019 1
hsa-mir-577 0.047 0.5
hsa-mir-590-3p 0.001 1
hsa-mir-628-5p 0.047 1
hsa-miR-758-3p 0.026 0.3
hsa-mir-767-3p 0.002 1
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The Kruskal–Wallis Test with Bonferroni correction identified nine of our 754 miRNAs tested to
correlate significantly with our VEGF expression and for PTEN, we could find 11 miRNAs with this
approach (Table 4) which is a highly significant overrepresentation of miRNAs identified (p <0.01).
In addition, all those miRNAs are predicted as VEGF, respectively PTEN targets in multiple (3 to 18)
different miRNA databases according to miRDIP [20].
Table 4. Correlation of VEGF and PTEN immunohistochemistry with miRNA expression and nr of
miRNA Databases, predicting these interactions.
miRNA, Correlation with VEGF A Kruskal–Wallis with Bonferroni Correction n of Predicted miRNA DatabasesAccording to miRDIP
hsa-mir-142-3p 0.011 6
hsa-mir-142-5p 0.015 4
hsa-miR-155-3p 0.038 3
hsa-mir-193a-3p 0.041 3
hsa-mir-24-2-5p 0.038 3
hsa-miR-379-5p 0.013 4
hsa-miR-500a-5p 0.018 3
hsa-miR-630 0.047 4
hsa-mir-942-5p 0.037 12
miRNA, Correlation with PTEN
hsa-miR-1-3p 0.023 8
hsa-miR-106a-5p 0.05 18
hsa-mir-17-5p 0.043 18
hsa-miR-190a-5p 0.025 8
hsa-miR-197-3p 0.035 6
hsa-miR-222-3p 0.004 10
hsa-miR-27b-3p 0.046 8
hsa-miR-372-3p 0.048 13
hsa-miR-381-3p 0.024 6
hsa-mir-508-3p 0.016 8
hsa-miR-642a-5p 0.035 11
Survival- and miRNA data were extracted from the TCGA dataset [21]. After correction for
multiple testing, no single miRNA was found to be significantly associated with a decreased relapse
free survival. This is reflected by a low statistical power with only 17 cases of PTC with an ACO in
the TCGA.
2.2. Immunohistochemical Analysis
PTEN protein expression was preserved in all patients of the control group (CG), whereas it was
lost in >50% of the ACO patients. VEGF on the other hand was preserved in about 40% of the control
cases while it was only expressed in 2% of the ACO patients. The detailed immunohistochemical
results are shown in Table 5.
Table 5. Correlation of relapse free survival and alteration of intensity in immunohistochemical staining
(univariate analysis).
Immunohistochemical Marker Control Group, n of Cases(Percentage of Cases)
Adverse Clinical Outcome
Group, n of Cases
(Percentage of Cases)
Probability Value
PTEN
(cytoplasmic)
negative 0 (0%) 68 (54.8%)
0.026
weak/moderate/strong 4 (3.2%) 52 (41.9%)
VEGF A
(cytoplasmic)
negative/weak 52 (42.3%) 16 (13%)
0.025
moderate/strong 51 (41.5%) 4 (2.2%)
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PTEN and VEGF-A were able to predict patient relapse on univariate analysis (Table 5,
Figures 1 and 2). Multivariate analyses, including tumor stage, age, gender, and TC morphology as
covariables were run and confirmed their independent prognostic role: PTEN (p = 0.002; Exp(B) 0.176)
and VEGF (p = 0.031; Exp(B) 3.118).
Further, VEGF protein expression was significantly positively associated with increased patient
age (p <0.014).
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2.3. TERT Pro oter utation nalysis
As reported [7], we an lyzed 53 tumor samples in the ACO group of which 8 ad a TERT promoter
mutati n, while 57 sampl s of the control group were TERT promoter mutati n negative (p < 0.002).
TERT promoter mutational status correlated neither with VEGF nor with PTEN protein expression
in univariate analysis, the factor which turned out to be ndepende t from TC mor h logy.
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Running TERT in a multivariate analysis with PTEN including tumor stage, age and gender as
covariables, TERT (p = 0.002; Exp(B) 3.737) and PTEN (p = 0.036; Exp(B) 0.259) were independent
parameters. On repeating the analysis, replacing PTEN with VEGF, both parameters were significant
as well: TERT (p = 0.019; Exp(B) 2.524) and VEGF (p = 0.038; Exp(B) 0.288).
2.4. Histopathological Evaluation
All cases were carefully re-examined by three independent pathologists (MSD, AS, AP). In cases
of discrepancy, a consensus diagnosis was rendered at a multiheaded microscope. The amount of TCs
was semiquantitatively assessed as previously described [7]. The ACO group consisted of 38 classic
PTC, 15 PTC of follicular variant, and 4 PTC of a special variant of which 36 had at least 10% of TC
as published [7]. Sixty-eight PTC cases without relapse, composed of 30 classic PTC, 32 FVPTC and
6 PTC of a special variant served as control group including 12 cases with at least 10% TC (Table 6).
Twenty-one tumors had lymph-node metastases and 6 had distant metastases.
Table 6. Clinicopathologic characteristics of the study collective with relapse after initial RAI (“adverse
outcome”, ACO) and the control group (CG), TC (tall cell), chi-square test.
Demographics Groups Patients Total(n = 125)
Patients ACO
(n = 57)
Patients CG
(n = 68) Probability Value
age age <48 69 (55.2%) 32 (25.6%) 37 (29.6%) p <0.859
age ≥48 56 (44.8%) 25 (20.0%) 31 (24.8%)
gender male 34 (27.2%) 20 (16.0%) 14 (11.2%) p <0.106
female 91 (72.8%) 37 (29.6%) 54 (43.2%)
pT-stage pT 1–2 55 (44.0%) 18 (14.4%) 37 (29.6%) p <0.012
pT 3–4 70 (56.0%) 39 (31.2%) 31 (24.8%)
TC
TC <10% 77 (61.6%) 21 (16.8%) 56 (44.8%) p <0.001
TC >10% 48 (38.4%) 36 (28.8%) 12 (9.6%)
2.5. Predictive Algorithm
By feeding TC, TERT promoter mutation status, patient age, and gender into the SPSS decision
tree CRT analysis tool, an algorithm was developed to render a diagnostic accuracy to predict patient
relapse of 73.6% only using TC-Morphology (Figure 3).
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the overall accuracy to 79.2% and the accuracy of tumor relapse prediction increases almost 15% up to
67% (Figure 4).
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3. Discussion
In the present study we searched for epigenetic changes on the miRNA level that were able to
predict patient outcome and identified a subset of those miRNAs to be potentially involved in TC
phenotype of PTC.
3.1. MiRNAs and Outcome
MiRNAs are small non-coding RNAs that regulate about two thirds of the human genome.
They are centrally involved in epigenetic gene regulation in basically every biological process as well as
in carcinogenesis, including thyroid cancer [11,12,22]. After extensive miRNA profiling, we provided
the first comprehensive list of in total 149 miRNAs associated with a decreased RFS in PTC.
The identification of miRNAs, which indicate an adverse outcome is not only interesting from
a scientific perspective but also from a diagnostic and prognostic point-of-view. This could help in
diagnostically difficult cases in which tall cells as a well-established morphological tool to predict an
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adverse outcome are not identified [7] and bring a more objective tool into the hand of a diagnostic
pathologist than the subjective identification of a small subpopulation of TC.
3.2. Validation of Dataset
Some of the miRNAs like miR-1, miR-23b, miR-34b, miR-146b, or miR-150 have already previously
been identified as markers of aggressiveness in thyroid cancer and could be confirmed in the present
study, underscoring the validity of our analysis [13,23]. Nevertheless, we aimed for a further,
more comprehensive validation of the miRNA data.
For this, we looked into genes which are known to play an important role in thyroid pathogenesis
and could be potentially regulated by those miRNA changes, and identified PTEN and VEGF. In fact,
a large number of miRNAs which were identified by us are predicted by various miRNA target
prediction databases to have PTEN or VEGF as a target and could be experimentally verified in thyroid
cancer and various other tumor types [20,24]. The miRNAs identified are significantly overrepresented
in the miRTarBase database of experimentally verified miRNA-protein targets [24]. If our miRNA
data had not been in an appropriate biological context, we would not have been able to find so many
experimentally verified miRNAs among the miRNAs which we identified to target VEGF and PTEN
based on our profiling data.
In addition, we found a significant correlation between PTEN and VEGF expression
and deregulated miRNAs in our dataset with a significant overrepresentation of known
miRNA–VEGF/PTEN interactions. While a thorough experimental validation is beyond the scope of
this work, we believe that this lays a solid foundation for an informed approach for further studies in
the field.
Of note, we also aimed to validate our miRNA profiling data results with the largest miRNA
PTC dataset available, the TCGA dataset [21]. The bioinformatic analysis revealed that not a single
significant miRNA predicted a decreased RFS in the TCGA dataset. We believe the reason is that the
statistical power in the TCGA concerning patients with an ACO is too low. To our knowledge, there is
no other dataset available for a direct cross-validation.
3.3. PTC-TC
PTC is the most common type of thyroid carcinoma. It is known to have a favorable prognosis
and is generally cured by partial or total thyroidectomy following RAI [6]. Nevertheless, a small
number of patients suffers from relapses and would therefore profit from a closer follow-up care.
Although several features have been discovered that correlate with a more aggressive clinical behavior,
not all patients that will show a relapse can be identified [7,25]. In a previous work, we showed that
only 10% of TCs in a single tumor are one of these strong predicting factors [7].
The identification of TC morphology seems easy at first hand but in daily routine it is nevertheless
often missed. This holds especially true when the percentage of TCs is low. Obviously, there is some
subjectivity in judging TC morphology. Therefore, the identification of biomarkers that help to gather
reliable prognostic information and where the read-out is more objective is of clinical importance.
3.4. PTEN
Altered PTEN expression plays an important role in human cancer development. Mutations of
PTEN have been detected in various other types of human carcinoma including breast cancer,
endometrial and thyroid carcinoma [14,26,27]. Despite this well-established knowledge, the prognostic
role of PTEN has to our knowledge not yet been systematically evaluated in a large cohort of PTC
patients. As expected, we found a decreased relapse-free survival in the case of PTEN protein loss.
Interestingly, this proved to be an adverse prognostic marker independent of TC morphology in a
multivariate analysis.
We found a loss of PTEN protein expression in more than 50% of cases in the ACO group. Since only
2–5% of PTC harbors a PTEN mutation according to the TCGA dataset and other studies [2,21], its loss
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of protein expression cannot be explained by mutations alone. One reason might be the epigenetic
post-translational inhibition/cleavage via the upregulated miRNAs identified. Some of them like
miR-17-5p or miR-222-3p are already experimentally verified targets of PTEN while for others this work
still has to be done [24]. All 32 miRNAs that we report to potentially target PTEN are upregulated and
may therefore very well be accountable for the loss of the observed PTEN protein expression. In addition,
all of them are significantly associated with a decreased RFS themselves in a Kaplan–Meier analysis.
3.5. VEGF
It has been known for a long time that VEGF plays a role in thyroid carcinomas [28] and first
tyrosine kinase inhibitors also targeting VEGF have been successfully tested in patients [29].
VEGF has been linked to increased patient age [17] which we could confirm in the present work.
We also found a loss of VEGF expression by immunohistochemistry to be associated with a decreased
relapse free survival in univariate and multivariate analysis, including strong confounding factors
like TC morphology. This finding is in contrast to previous reports claiming that an increased VEGF
expression might predict increased local or distant recurrence [30,31]. One strength of the present
study is the fact that we have included a large number of patients with an adverse clinical outcome.
This enables us to overcome statistical limitations resulting in a too small number of patients with
these rare adverse events. In addition, opposite results might also be partially due to different VEGF
antibodies. Klein et al. used one which detected the isoform VEGF-A-206 which is not detected by the
antibody used in the present study [30]—we detected the 165, 189, and 121 amino acid splice variants
of VEGF.
A closer look at the VEGF gene itself is certainly worthwhile. The VEGF gene underlies differential
splicing into several isoforms that differ from each other regarding the inclusion of the exons 6 and
7 into the transcript of the gene, which is responsible for the binding of the protein to extracellular
matrix heparin. This results in the diffusible isoform VEGF-A121 at one end of the spectrum and in the
strongly heparin binding isoform VEGF-A189 on the other [32]. Thus, it can be assumed that VEGF
protein expression measured by immunohistochemistry corresponds to the tissue bound isoforms
but does not provide any information concerning the presence and amount of the soluble isoforms.
Since VEGF is secreted and high serum VEGF levels correlate with advanced tumor stages and lymph
node metastases, it may thus well be possible that we observe a loss of VEGF expression on the
immunohistochemical level in certain tumors because all VEGF has been secreted into the blood
stream [33]. This would explain the high VEGF levels in serum and decreased VEGF expression by
immunohistochemistry in patients who nevertheless might respond to VEGF inhibitors. Unfortunately,
there is no study available correlating the immunohistochemical expression of VEGF with VEGF serum
levels and in our patients, serum is not available in order to test this hypothesis.
3.6. PTEN, VEGF, TERT, TC and a Diagnostic Algorithm
The strong association of TERT promoter mutations and ACO has been well documented [7,34].
Here, we tested PTEN and VEGF in multivariate analyses together with TERT. Interestingly, all three
were independent of TC morphology and were significantly able to predict an ACO. This gives us
two new immunohistochemical tools to predict patient outcome, which is especially helpful since
TERT promoter mutations occur only in a minority of 6–8% of cases and a reliable morphological
diagnosis of TC is unfortunately still subjective and requires a lot of expertise. Although 10% of TC
are already significantly associated with an ACO, different results are obtained by controlling for age,
pT stage, gender, and TERT promoter mutation status. In this case, 20% TC is identified as the better
overall cut-off to identify patients with a tumor relapse. This makes also sense from a morphological
point-of-view, because a very low percentage of TC is inherently associated with false-positive cases.
This is the moment, where VEGF and PTEN staining may come into place as they are not able to
replace a thorough morphological workup, but their expression pattern can help to render a more
accurate patient prognosis. Beyond morphology, implementing them into a diagnostic algorithm is
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mainly beneficial in order to predict tumor relapse in PTC with only a small percentage of TC which
are in daily routine diagnostics, and indeed the difficult cases in the tumorboard decisions.
4. Material and Methods
4.1. Tissue Samples and Patient Characteristics
MiRNA profiling was performed on a patient cohort of 44 PTC (Table 7).
Table 7. Clinicopathologic characteristics of a subset of the study collective which underwent miRNA
profiling; adverse outcome (ACO), control group (CG), TC (tall cell), chi-square test.
Demographics Groups Patients Total (n) Patients ACO (n =29) Patients CG (n = 15) Probability Value
age age < 48 21 (47.7%) 15 (34.1%) 6 (13.6%) p < 0.535
age ≥ 48 23 (52.3%) 14 (31.8%) 9 (20.5%)
gender male 16 (36.4%) 11 (25%) 5 (11.4%) p < 1
female 28 (63.6%) 18 (40.9%) 10 (22.7%)
pT-stage pT 1–2 8 (18.2%) 5 (11.4%) 3 (6.8%) p < 1
pT 3–4 36 (81.8%) 24 (54.4%) 12 (27.3%)
TC
TC <10% 20 (45.5%) 8 (18.2%) 12 (27.3%) p < 0.001
TC >10% 24 (54.5%) 21 (47.7%) 3 (6.8%)
This cohort was part of a larger patient collective of 57 PTC with a relapse after initial thyroidectomy
and radioiodine therapy (RAI) and an age-, stage- and gender-matched control group of 68 PTC
without relapse. The details of this patient collective have been reported previously [7]. In short, the
study collective was built in collaboration with the departments of nuclear medicine in the Canton
Zurich (University Hospital Zürich, City Hospital Triemli, Cantonal Hospital Winterthur) where the
patients‘ follow-up care was conducted and cases with a relapse could be identified. This enabled us
to enrich the collective with tumors harboring an adverse outcome, overcoming statistical problems
with low numbers of ACO patients. Tumors with a diameter of less than 1 cm were excluded from
the analysis due to their indolent clinical course [35]. Surgical resection had been performed between
1990 and 2006, following RAI. The mean ± st.dev. follow-up-time for relapse free survival (RFS) was
51.78 ± 50.97 months.
The tissue of the study collective was taken from the archives of the corresponding Institutes of
Pathology of the Canton Zurich; the tissue of the control collective was taken from the archives of
the Institute of Pathology of the University hospital Zurich. After revision of the initial diagnosis by
three board certified pathologists (MD, AS, AP) according to the 2017 WHO classification [25] and the
current UICC TNM-classification (8th edition) [36], our study collective comprised a total of 125 PTCs
including 57 cases with adverse clinical outcome (Table 6).
The study was conducted after approval of the responsible cantonal ethics committee (STV 28-2006).
4.2. RNA Isolation and miRNA Expression Analysis
Tumor areas and non-neoplastic tissue areas with a high purity (>80%) were marked for
microdissection on six blank consecutive slides (each 15 µm) under guidance of a stereomicroscope
(Olympus SZ61, Hamburg, Germany). RNA was extracted with the RecoverAll kit (Ambion,
Life Technologies, Carlsbad, CA, USA) and miRNA expression analysis was performed in tumorous
(n = 44) and non-neoplastic (n = 8) thyroid FFPE tissue samples as previously described [11,12].
RNA quality and quantity was assessed with a spectrophotometer (NanoDrop 1000, Thermo Fisher
Scientific, Wilmington, DE, USA), following pre-amplification and miRNA expression profiling using
TaqMan RT-PCR microarray version v3.0 on the ABI 7900 platform which was designed to detect
754 human miRNA’s (Applied Biosystems Life Technologies, Carlsbad, CA, USA). RNU44 and U6
snRNA were used for normalization of RNA and non-human miRNA ath-miR-159a served as a
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negative control. miRNA expression levels were calculated using the 2-∆∆ct method using Dataassyst
v3.1 software (Applied Biosystems). The maximum allowed Ct value for calculations was 37.
4.3. Immunohistochemical Analyses
A tissue micro array (TMA) was constructed as described previously [37] including a 0.6 mm core
of tumor and normal tissue of histologically preselected regions of each case. A pathologist (MSD)
blinded to the clinical data preselected tissue regions. Slides of 2 µm of the TMA were cut using a
rotation microtome and immunohistochemical staining for PTEN, and VEGF-A protein expression was
performed according to standard immunohistochemical techniques (Table S1). The VEGF antibody
reacts with the 165, 189, and 121 amino acid splice variants of VEGF in humans. The markers were
chosen by literature research [14,17]. The analysis of the immunohistochemical staining was conducted
by a pathologist (MSD), who was blinded to the clinical data. The intensity of the staining (negative,
weak, moderate, or strong) as well as the percentage of stained cells in the cytoplasm were recorded.
4.4. TERT Promoter Mutation Analysis
All tumors underwent TERT promoter mutation testing as described and previously reported [7].
4.5. Statistical Analysis
SPSS statistical software 24.0 (SPSS, Chicago, IL, USA) was used for assessment of the sample
distribution (Kolmogorov–Smirnov test), the correlation of the clinicopathological data and the
expression of the immunohistochemical markers with the Chi-Square test. For multivariate analysis
(Cox regression) the factors age, pT-stage, gender, and TC morphology >10% were used as covariates.
Survival analysis was calculated with Kaplan–Meier curves (log rank) and associations between
miRNA expression and immunohistochemical data were calculated with the Kruskal–Wallis H test
with Bonferroni correction. A p-value of <0.05 was considered statistically significant. MirDIP and
miRTarBase were used for bioinformatic miRNA target prediction and identification of validated
miRNA-protein-interactions [6,24].
5. Conclusions
Our data provides the most up-to-date comprehensive list of miRNAs linked to an adverse clinical
outcome in PTC patients and lays the foundation for further informed basic research studies in this
field. PTEN and VEGF are significant adverse prognostic factors in patients with PTC and a flow
chart is proposed to identify patients with an adverse outcome. PTEN and VEGF are independent of
other major prognostic factors including clinical features like age, tumor stage, and gender, molecular
aberrations like TERT, and morphological factors like TCs. A variety of different miRNAs is highly
likely to be responsible for this observation.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/6/885/s1,
Table S1: Technical details of immunohistochemical stains.
Author Contributions: L.A.B., A.S., A.P. and M.S.D. wrote the manuscript. A.S., A.P. and M.S.D. reclassified the
tumors. M.S.D. evaluated the immunohistochemistry. M.S.D. and C.S. calculated the statistics. H.M., P.K. and I.M.
contributed with intellectual input and patient samples. MiRNA analyses were done by M.S.D. in the lab and of
Y.E.N. and M.N.N. under their supervision.
Funding: M.S.D. was supported by the Fondation pour la recherche Nuovo-Soldati, the Research Support
Foundation, the Gertrud Hagmann Stiftung für Malignomforschung and the Berner Krebsliga.
Acknowledgments: We thank H. Steinert, A. Haldemann and A. Meili for providing us with clinicopathological
data from their nuclear medicine departments. We also thank R. Flury, Cantonal hospital Winterthur, C. Moll,
Cantonal hospital Münsterlingen, J. Diebold, Cantonal hospital Luzern, A. von Hochstetter, Institut Enge, C.
Scheidegger, Viollier Basel, T. Baltisser, Institut Regenbogen, and H.-M. Riehle, Institut Arnaboldi, for providing
tissue samples and for their helpful collaboration. Finally, we thank I. Zlobec for reviewing the manuscript and
the Tissue Bank Bern for technical support.
Conflicts of Interest: The authors declare no conflict of interest.
Cancers 2019, 11, 885 17 of 18
References
1. Hundahl, S.A.; Fleming, I.D.; Fremgen, A.M.; Menck, H.R. A National Cancer Data Base report on 53,856 cases
of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 1998, 83, 2638–2648. [CrossRef]
2. Diagnostic Pathology and Molecular Genetics of the Thyroid, 2nd ed.; Nikiforov, Y.E.; Biddinger, P.W.;
Thompson, L.D. (Eds.) Lippincott Williams & Wilkins (LWW): Philadelphia, PA, USA, 2012; p. 436.
3. Dettmer, M.; Schmitt, A.; Steinert, H.; Haldemann, A.; Meili, A.; Moch, H.; Komminoth, P.; Perren, A.
Poorly differentiated thyroid carcinomas: How much poorly differentiated is needed? Am. J. Surg. Pathol.
2011, 35, 1866–1872. [CrossRef] [PubMed]
4. Schurch, C.M.; Roelli, M.A.; Forster, S.; Wasmer, M.H.; Bruhl, F.; Maire, R.; Di Pancrazio, S.; Ruepp, M.D.;
Giger, R.; Perren, A.; et al. Targeting CD47 in anaplastic thyroid carcinoma enhances tumor phagocytosis by
macrophages and is a promising therapeutic strategy. Thyroid 2019. [CrossRef] [PubMed]
5. Dettmer, M.; Schmitt, A.; Steinert, H.; Moch, H.; Komminoth, P.; Perren, A. Poorly differentiated oncocytic
thyroid carcinoma—Diagnostic implications and outcome. Histopathology 2012, 60, 1045–1051. [CrossRef]
[PubMed]
6. Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.;
Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association Management
Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American
Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid
2016, 26. [CrossRef] [PubMed]
7. Dettmer, M.S.; Schmitt, A.; Steinert, H.; Capper, D.; Moch, H.; Komminoth, P.; Perren, A. Tall cell papillary
thyroid carcinoma: New diagnostic criteria and mutations in BRAF and TERT. Endocr. Relat. Cancer 2015, 22,
419–429. [CrossRef] [PubMed]
8. LiVolsi, V.A. Papillary carcinoma tall cell variant (TCV): A review. Endocr. Pathol. 2010, 21, 12–15. [CrossRef]
9. Bartels, C.L.; Tsongalis, G.J. MicroRNAs: Novel biomarkers for human cancer. Clin. Chem. 2009, 55, 623–631.
[CrossRef]
10. Nikiforova, M.N.; Tseng, G.C.; Steward, D.; Diorio, D.; Nikiforov, Y.E. MicroRNA expression profiling of
thyroid tumors: Biological significance and diagnostic utility. J. Clin. Endocrinol. Metab. 2008, 93, 1600–1608.
[CrossRef]
11. Dettmer, M.; Perren, A.; Moch, H.; Komminoth, P.; Nikiforov, Y.E.; Nikiforova, M.N.
Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary
thyroid carcinoma. Thyroid 2013, 23, 1383–1389. [CrossRef]
12. Dettmer, M.; Vogetseder, A.; Durso, M.B.; Moch, H.; Komminoth, P.; Perren, A.; Nikiforov, Y.E.;
Nikiforova, M.N. MicroRNA expression array identifies novel diagnostic markers for conventional and
oncocytic follicular thyroid carcinomas. J. Clin. Endocrinol. Metab. 2013, 98, E1–E7. [CrossRef] [PubMed]
13. Dettmer, M.S.; Perren, A.; Moch, H.; Komminoth, P.; Nikiforov, Y.E.; Nikiforova, M.N. MicroRNA profile of
poorly differentiated thyroid carcinomas: New diagnostic and prognostic insights. J. Mol. Endocrinol. 2014,
52, 181–189. [CrossRef]
14. Gimm, O.; Perren, A.; Weng, L.P.; Marsh, D.J.; Yeh, J.J.; Ziebold, U.; Gil, E.; Hinze, R.; Delbridge, L.;
Lees, J.A.; et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and
benign and malignant epithelial thyroid tumors. Am. J. Pathol. 2000, 156, 1693–1700. [CrossRef]
15. Leslie, N.R.; Brunton, V.G. Cell biology. Where is PTEN? Science 2013, 341, 355–356. [CrossRef] [PubMed]
16. Carmeliet, P.; Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473,
298–307. [CrossRef] [PubMed]
17. de Araujo-Filho, V.J.; Alves, V.A.; de Castro, I.V.; Lourenco, S.V.; Cernea, C.R.; Brandao, L.G.; Ferraz, A.R.
Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma. Thyroid 2009, 19,
1233–1237. [CrossRef] [PubMed]
18. Yeung, K.T.; Cohen, E.E. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid
Carcinoma. Clin. Cancer Res. 2015, 21, 5420–5426. [CrossRef] [PubMed]
19. Agarwal, V.; Bell, G.W.; Nam, J.W.; Bartel, D.P. Predicting effective microRNA target sites in mammalian
mRNAs. eLife 2015, 4, e05005. [CrossRef]
Cancers 2019, 11, 885 18 of 18
20. Shirdel, E.A.; Xie, W.; Mak, T.W.; Jurisica, I. NAViGaTing the micronome–Using multiple microRNA
prediction databases to identify signalling pathway-associated microRNAs. PLoS ONE 2011, 6, e17429.
[CrossRef]
21. Cancer Genome Atlas Research, N. Integrated genomic characterization of papillary thyroid carcinoma. Cell
2014, 159, 676–690.
22. Farazi, T.A.; Spitzer, J.I.; Morozov, P.; Tuschl, T. miRNAs in human cancer. J. Pathol. 2011, 223, 102–115.
[CrossRef] [PubMed]
23. Yip, L.; Kelly, L.; Shuai, Y.; Armstrong, M.J.; Nikiforov, Y.E.; Carty, S.E.; Nikiforova, M.N. MicroRNA signature
distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann. Surg. Oncol. 2011, 18,
2035–2041. [CrossRef] [PubMed]
24. Chou, C.H.; Chang, N.W.; Shrestha, S.; Hsu, S.D.; Lin, Y.L.; Lee, W.H.; Yang, C.D.; Hong, H.C.; Wei, T.Y.;
Tu, S.J.; et al. miRTarBase 2016: Updates to the experimentally validated miRNA-target interactions database.
Nucleic. Acids Res. 2016, 44, D239–D247. [CrossRef] [PubMed]
25. Lloyd, R.V.; Osamura, R.Y.; Klöppel, G.; Rosai, J. WHO Classification of Tumours of Endocrine Organs, 4th ed.;
International Agency for Research on Cancer (IARC): Lyon, France, 2017.
26. Perren, A.; Weng, L.P.; Boag, A.H.; Ziebold, U.; Thakore, K.; Dahia, P.L.; Komminoth, P.; Lees, J.A.;
Mulligan, L.M.; Mutter, G.L.; et al. Immunohistochemical evidence of loss of PTEN expression in primary
ductal adenocarcinomas of the breast. Am. J. Pathol. 1999, 155, 1253–1260. [CrossRef]
27. Terakawa, N.; Kanamori, Y.; Yoshida, S. Loss of PTEN expression followed by Akt phosphorylation is a poor
prognostic factor for patients with endometrial cancer. Endocr. Relat. Cancer. 2003, 10, 203–208. [CrossRef]
[PubMed]
28. Jo, Y.S.; Li, S.; Song, J.H.; Kwon, K.H.; Lee, J.C.; Rha, S.Y.; Lee, H.J.; Sul, J.Y.; Kweon, G.R.; Ro, H.K.; et al.
Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary
thyroid cancer. J. Clin. Endocrinol. Metab. 2006, 91, 3667–3670. [CrossRef] [PubMed]
29. Schlumberger, M.; Tahara, M.; Wirth, L.J.; Robinson, B.; Brose, M.S.; Elisei, R.; Habra, M.A.; Newbold, K.;
Shah, M.H.; Hoff, A.O.; et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl.
J. Med. 2015, 372, 621–630. [CrossRef]
30. Klein, M.; Vignaud, J.M.; Hennequin, V.; Toussaint, B.; Bresler, L.; Plenat, F.; Leclere, J.; Duprez, A.; Weryha, G.
Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary
thyroid carcinoma. J. Clin. Endocrinol. Metab. 2001, 86, 656–658. [CrossRef]
31. Kilicarslan, A.B.; Ogus, M.; Arici, C.; Pestereli, H.E.; Cakir, M.; Karpuzoglu, G. Clinical importance of vascular
endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS 2003, 111, 439–443. [CrossRef]
32. Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its
receptors. FASEB J. 1999, 13, 9–22. [CrossRef]
33. Yu, X.M.; Lo, C.Y.; Lam, A.K.; Leung, P.; Luk, J.M. Serum vascular endothelial growth factor C correlates
with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann. Surg. 2008,
247, 483–489. [CrossRef]
34. George, J.R.; Henderson, Y.C.; Williams, M.D.; Roberts, D.B.; Hei, H.; Lai, S.Y.; Clayman, G.L. Association of
TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC. J. Clin. Endocrinol. Metab.
2015, 100, E1550–E1559. [CrossRef]
35. Baloch, Z.W.; LiVolsi, V.A. Microcarcinoma of the thyroid. Adv. Anat. Pathol. 2006, 13, 69–75. [CrossRef]
36. James, D.; Brierley, M.K.G. Christian Wittekind. TNM Classification of Malignant Tumours, 8th ed.;
Wiley-Blackwell: Hobroken, NJ, USA, 2017; p. 272.
37. Boos, L.A.; Dettmer, M.; Schmitt, A.; Rudolph, T.; Steinert, H.; Moch, H.; Sobrinho-Simoes, M.; Komminoth, P.;
Perren, A. Diagnostic and prognostic implications of the PAX8-PPARgamma translocation in thyroid
carcinomas-a TMA-based study of 226 cases. Histopathology 2013, 63, 234–241. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
